Inavolisib NEW
| Price | $80 | $223 | $392 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-12 |
Product Details
| Product Name: Inavolisib | CAS No.: 2060571-02-8 |
| Purity: 99.87% | Supply Ability: 10g |
| Release date: 2026/05/12 |
Product Introduction
Bioactivity
| Name | Inavolisib |
| Description | Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. |
| In vitro | METHODS: Cell viability was assayed using Inavolisib (GDC-00777) up to 100 μmol/L in a panel of cancer cell lines. RESULTS Inavolisib (GDC-00777) is a stronger cellular antiproliferative inducer. [1] |
| In vivo | METHODS: p110a protein depletion was studied in a p110a mutant xenograft breast cancer model using Inavolisib (GDC-0077) at a single oral dose of 50 mg/kgDC-0077. RESULTS Inavolisib (GDC-0077) depleted p110a protein expression for up to 8 hours. [1] |
| Storage | Store at low temperature,Keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (24.55 mM), Solution. DMSO : 240 mg/mL (589.15 mM), Sonication is recommended. |
| Keywords | RG-6114 | RG 6114 | PI3Kα | PI3K | Phosphoinositide 3-kinase | Inhibitor | inhibit | Inavolisib | GDC0077 | GDC 0077 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-08 | ||
|
Hubei Chuchang Biotech Co., Ltd.
|
2025-03-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY